
BMJ Open, Год журнала: 2025, Номер 15(3), С. e090986 - e090986
Опубликована: Март 1, 2025
Objectives SARS-CoV-2 poses significant challenges to people living with diabetes (PLWD). This systematic review aimed explore the impact of COVID-19 on mortality, complications associated and haematological parameters among PLWD. Design Systematic meta-analysis using Grading Recommendations Assessment, Development Evaluation (GRADE). Data sources EMBASE, MEDLINE, Cochrane Central Register Controlled Trials LILACS were searched between 1 December 2019 14 January 2025. Eligibility criteria for selecting studies Eligible included case-control cohort involving PLWD categorised into two groups: those confirmed infection without. extraction synthesis Meta-analyses estimated odds ratios (ORs) mean differences (MDs) outcomes including intensive care unit (ICU) admission, diabetic ketoacidosis (DKA), acute kidney injury, hospitalisation length parameters. We pooled results random-effects models assessed study quality Newcastle-Ottawa Scale. A funnel plot was used detect potential publication bias. The overall certainty evidence GRADE. Results 25 7266 unique eligible, 154674 (561 558 593 116 without COVID-19). in significantly increased mortality (OR 2.52, 95% CI 1.45 4.36, I 2 =99%), injury (3.69, 2.75 4.94, =0%), random plasma glucose subjects type (MD 20.38 mg/dL, 7.39 33.36, haemoglobin A1C (0.21%, 0.05 0.38, =13%), creatinine (0.12 0.04 0.19, C reactive protein (38.30 mg/L, 4.79 71.82, =82%) D-dimer (1.52 µg/mL, 0.73 2.31, =0%). No observed incidence ICU admission DKA, length, haemoglobin, leucocyte, lymphocyte, neutrophil lymphocyte ratio, platelet, blood urea nitrogen, glomerular filtration rate, procalcitonin, albumin, ferritin bilirubin infection. Conclusions is elevated risks poor glycaemic control PLWD, alongside levels inflammatory coagulation biomarkers. These findings underscore urgent need tailored clinical management strategies COVID-19. PROSPERO registration number CRD42023418039.
Язык: Английский